



Charles F. Wagner

Executive Vice President and Chief Financial Officer

Charles (Charlie) Wagner joined Vertex Pharmaceuticals in 2019 as Executive Vice President and Chief Financial Officer (CFO). In this role, Mr. Wagner oversees the finance, internal audit, investor relations and global security and facilities functions. Mr. Wagner has deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.

Prior to joining Vertex, Mr. Wagner was Executive Vice President, Finance and CFO at Ortho Clinical Diagnostics — a Carlyle Group portfolio company. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprise-wide projects. Prior to this, Mr. Wagner served as CFO for Bruker Corporation, Progress Software Corporation and Millipore Corporation. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand.

From April 2014 to August 2017, Mr. Wagner served as a director and chairman of the Audit Committee of Good Start Genetics. He previously served as a director of Bruker Corporation and a member of the Audit Committee from August 2010 to June 2012. Mr. Wagner holds a B.S. in accounting from Boston College and an M.B.A. from Harvard Business School.

Contact:

Charles F. Wagner

Executive Vice President and Chief
Financial Officer

he/him/his

Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
+1 (617) 341-6100
global.vrtx.com

Joined Vertex: 2019

Education:

Boston College
Harvard University